therapy

Plum Tree Leads the Way in Team-Based Child Therapy and Multidisciplinary Testing

ST. CHARLES, IL, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Plum Tree Psychology, a trusted child and family mental health practice…

6 months ago

Sirtex Receives Expanded CE Mark Approval for SIR-Spheres Y-90 Resin Microspheres

Broadened indication increases access to liver cancer treatment across Europe and CE-marked territories. WOBURN, Mass., Sept. 8, 2025 /PRNewswire/ --…

6 months ago

CBM India and SBI Foundation Launch New Initiative to Empower 200 Children with Disabilities in Madhya Pradesh

The project brings essential therapy, assistive devices, and learning support to children with disabilities in villages where such services are…

6 months ago

Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism

September 06, 2025 14:30 ET  | Source: BridgeBio Pharma, Inc. - 80% of post-surgical hypoparathyroidism participants achieved concomitant blood and…

6 months ago

Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology

SALT LAKE CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing…

6 months ago

Gateway to Growth: Innovation and Opportunity at the 8th CIIE

SHANGHAI, Aug. 29, 2025 /PRNewswire/ -- Amid a shifting global economy, the China International Import Expo (CIIE) continues to provide a…

6 months ago

PEMF Therapy Emerges as a Leading 2025 Wellness Trend for Drug-Free Pain Relief; Grooni Earthings Pro Collection Meets Rising Demand

SHERIDAN, WY , Aug. 26, 2025 (GLOBE NEWSWIRE) -- As consumers seek science-informed, non-pharmacological options for chronic pain and recovery,…

6 months ago

Regen BioPharma Discusses Potential Impact of HemaXellerate on Chemotherapy Treament Market

SAN DIEGO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) today provided further insight…

7 months ago

Anbogen Receives FDA Clearance to Initiate Phase 1/2 Trial of ABT-301 Triplet Therapy for Advanced Colorectal Cancer

TAIPEI, Aug. 4, 2025 /PRNewswire/ -- Anbogen Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved…

7 months ago

Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Mechelen, Belgium; August 6, 2025, 7:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today…

7 months ago